﻿<?xml version="1.0" encoding="UTF-8"?>
<records>
  <record>
    <language>eng</language>
    <publisher>Science and Education Publishing</publisher>
    <journalTitle>American Journal of Microbiological Research</journalTitle>
    <eissn>2328-4137</eissn>
    <publicationDate>2021-10-12</publicationDate>
    <volume>9</volume>
    <issue>4</issue>
    <startPage>103</startPage>
    <endPage>106</endPage>
    <doi>10.12691/ajmr-9-4-1</doi>
    <publisherRecordId>AJMR2021941</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">Efficacy of the Vaccines, Their Safety, and Immune Responses against SARS-CoV-2 Infections</title>
    <authors>
      <author>
        <name>Mahendra Pal</name>
        <email>palmahendra2@gmail.com</email>
        <affiliationId>1</affiliationId>
      </author>
      <author>
        <name>Kirubel Paulos Gutama</name>
        <affiliationId>2</affiliationId>
      </author>
    </authors>
    <affiliationsList>
      <affiliationName affiliationId="1">Narayan Consultancy on Veterinary Public Health and Microbiology, Anand, India</affiliationName>
      <affiliationName affiliationId="2">Adaba Woreda Livestock and Fishery Resource Development Office, West Arsi, Ethiopia</affiliationName>
    </affiliationsList>
    <abstract language="eng">The search for vaccines has been a high priority since the worldwide COVID-19 pandemic was declared. Currently, mRNA-based vaccines, adenovirus-based vaccines, inactivated virus vaccines, and other vaccine platforms are all employed to combat the SARS-CoV-2 virus. BNT162b2 and mRNA-1273 are mRNA-based vaccines. The vaccination appears to be effective against SARS-CoV-2 strains that have emerged since the first study. They have primarily minor side effects, and there are no major safety concerns. Adenovirus-based vaccines are delivered by genetic cargo that is based on non-replicating adenovirus vectors that can increase immune response without the need of adjuvants. This is the case for Ad26.CoV2.S, ChAdOx1 nCoV-19/AZD1222, Gam-COVID-Vac/Sputnik V andAd5-based COVID-19 vaccine. There have been no known incidences of allergy to adenovirus vaccines, unlike mRNA vaccines. Inactivated virus vaccines are a common form of vaccine that has been used for decades. The goal is to render the virus non-infectious while preserving immunogenicity with high-quality antigens in order to trigger an immune response. The researched formaldehyde-inactivated whole-virus SARS-CoV2 vaccine (CoronaVac), as well as WIV04 and HB02, utilize this sort of vaccine formulation. A recombinant protein nanoparticle vaccine named NVX-CoV2373 is made up of trimeric spike glycoproteins with a potent Matrix-M1 adjuvant. Against the variant B.1.1.7 (Alpha), the vaccine appeared to be very effective. Vaccine efficacy against the B.1.351 (Beta) strain, on the other hand, proved to be lower.</abstract>
    <fullTextUrl format="pdf">http://pubs.sciepub.com/ajmr/9/4/1/ajmr-9-4-1.pdf</fullTextUrl>
    <keywords language="eng">
      <keyword>COVID-19</keyword>
      <keyword>efficacy</keyword>
      <keyword>immune response</keyword>
      <keyword>safety</keyword>
      <keyword>vaccines</keyword>
    </keywords>
  </record>
</records>